Exelixis Inc

1EXEL

Company Profile

  • Business description

    Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

  • Contact

    1851 Harbor Bay Parkway
    AlamedaCA94502
    USA

    T: +1 650 837-7000

    E: [email protected]

    https://www.exelixis.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    1,147

Stocks News & Analysis

stocks

Nvidia Earnings: No signs of a slowdown in demand for AI chips

A selloff in Nvidia stock on the earnings news looks like a buying opportunity to us.
stocks

ASX results reaction: WiseTech, Woolies, Sigma and more

A round up of notable stories and reactions as ASX reporting season rolls on.
stocks

WiseTech result disappoints, but the future looks bright

Markets appear underwhelmed by recent sales growth, however, our kingmaker thesis is intact.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,243.009.000.10%
CAC 407,703.9058.70-0.76%
DAX 4023,902.21137.71-0.57%
Dow JONES (US)45,544.8892.02-0.20%
FTSE 1009,187.3429.48-0.32%
HKSE25,077.6278.800.32%
NASDAQ21,455.55249.61-1.15%
Nikkei 22542,718.47110.32-0.26%
NZX 50 Index12,930.7327.650.21%
S&P 5006,460.2641.60-0.64%
S&P/ASX 2008,973.104.100.05%
SSE Composite Index3,857.9314.330.37%

Market Movers